Telbivudine: A novel nucleoside analog for chronic hepatitis B

Annals of Pharmacotherapy

Volumn 40, Issue 3, 2006, Pages 472-478

  Kim, Jiwon W ^a,b   Park, Susie H ^a   Louie, Stan G ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b USC UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

L thymidine; Hepatitis B; Nucleosides; Telbivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DNA POLYMERASE; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; TELBIVUDINE; THYMIDINE; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEPATITIS B; HUMAN; KIDNEY DYSFUNCTION; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES;

EID: 33645048707     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G027     Document Type: Review

References (35)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
3. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
4. Schmilovitz H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24:547-51.
5. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
6. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon in patients with hepatitis Be antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
7. Perillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
8. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9.
9. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
10. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341: 1256-63.
11. Liaw YF, Cheung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
12. Honkoop P, de Man RA, Niesters HO, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
13. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
15. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8.
16. Product information. Baraclude (entecavir). Princeton, NJ: Bristol-Myers Squibb, March 2005.
17. Bryant ML, Bridges EG, Placidi L, et al. Antiviral β-L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001;45:229-35.
18. Semizarov DG, Arzumanov AA, Dyatkina NB, et al. Stereoisomers of deoxynucleoside 5′-triphosphates as substrates for template-dependent and -independent DNA polymerase. J Biol Chem 1997;272:9556-60.
19. Whittington R, Brogden RN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992;44:656-83.
20. Wilde IM, Langtry HD. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1993;46: 515-78.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
22. Zhou XJ, Lim SG, Lai CL, Pow DM, Brown NA, Myers MW. Pharmacokinetics of beta-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection (abstract). Antiviral Res 2001;Hep-Dart abstracts:92.
23. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-26. DOI 10.1002/hep.2037
24. Zhou XJ, Myers M, Chao G, Dubuc G, Brown NA. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function (abstract). J Hepatol 2004;40 (suppl 1):S134.
25. Gish RG, Leung NW, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46: 1734-40.
26. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 2002;22:121-6.
27. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-402.
28. Wang CC, Holte S, Huang ML, et al. Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily. J Viral Hepatitis 2004;11:443-7.
29. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-9.
30. Wolters LM, Hansen BE, Niesters HG, De Hertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44.
31. Han SH, Leung NY, Teo EK, et al. Results of a one-year international phase IIb trial of LdT, and LdT plus lamivudine, in patients with chronic hepatitis B (abstract). J Hepatol 2004;40(suppl 1):S16.
32. Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004; s48:3702-10.
33. Poynard T, Lai CL, Leung NY, et al. Improving antiviral therapy in chronic hepatitis B: maximal viral suppression at week 24 correlates with better clinical efficacy at one year (abstract). J Hepatol 2004;40 (suppl 1):S130.
34. Delaney W, Yang H, Miller M, Gibbs C, Xiong S. Lamivudine-resistant HBV is cross-resistant to LdT and LcT in vitro. J Hepatol 2002;36(suppl 1):89.
35. Zhou XJ, Lloyd DM, Fielman BA, Maureen MW, Chao C. Absence of pharmacokinetic drug-drug interaction between telbivudine and lamivudine or adefovir in healthy subjects (abstract). J Hepatol 2005;40(suppl 2):S197-8.